TARA
Protara Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.94
−0.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 90.0K | 362.0K | — | 341.0K | — |
| Gross Profit | (90.0K) | (362.0K) | — | (341.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 53.1M | 42.6M | 31.7M | 24.8M | 16.8M |
| SG&A Expense | 23.6M | 21.9M | 17.4M | 18.6M | 20.7M |
| General & Admin Expense | 23.6M | 21.9M | 17.4M | 18.6M | 20.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (362.0K) | — | (137.0K) | 29.5M |
| Total Operating Expenses | 76.7M | 64.2M | 49.2M | 43.3M | 67.1M |
| Cost and Expenses | 76.8M | 64.5M | 49.2M | 43.6M | 67.1M |
| Operating Income (EBIT) | (76.8M) | (64.5M) | (49.2M) | (43.6M) | (67.1M) |
| Non-Operating | |||||
| Interest Income | 4.8M | 6.3M | 4.1M | 2.7M | 1.1M |
| Interest Expense | — | — | — | — | 1.1M |
| Net Interest Income | 4.8M | 6.3M | 4.1M | 2.7M | (27.0K) |
| Other Non-Op Income/Expense | 6.8M | 7.1M | 4.6M | 3.2M | 1.1M |
| Non-Operating Income (excl Interest) | (6.8M) | (7.1M) | (4.6M) | (3.2M) | (2.2M) |
| EBT (Pre-Tax Income) | (70.0M) | (57.4M) | (44.6M) | (40.4M) | (66.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (70.0M) | (57.4M) | (44.6M) | (40.4M) | (66.0M) |
| Earnings from Cont. Ops | (70.0M) | (57.4M) | (44.6M) | (40.4M) | (66.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (70.0M) | (57.4M) | (44.6M) | (40.4M) | (66.0M) |
| Per Share | |||||
| Basic EPS | ($1.36) | ($1.34) | ($2.17) | ($3.57) | ($5.86) |
| Diluted EPS | ($1.36) | ($1.34) | ($2.17) | ($3.57) | ($5.86) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 61.0M | 42.8M | 20.6M | 11.3M | 11.3M |
| Diluted Shares Outstanding | 61.0M | 42.8M | 20.6M | 11.3M | 11.3M |
| Profitability Metrics | |||||
| EBITDA | (69.7M) | (57.1M) | (44.3M) | (40.1M) | (64.6M) |
| D&A | 343.0K | 362.0K | 332.0K | 341.0K | 248.0K |
| EBIT | (70.0M) | (57.4M) | (44.6M) | (40.4M) | (64.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026